VANCOUVER, BC / ACCESSWIRE / March 14, 2021 / Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (FRA:LD62) (WKN: A2P8K3) (the "Company") a research and technology company focused on life sciences and bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, is pleased to announce that the Financial Industry Regulatory Authority has accepted the Company's Form 211 for filing and that its common shares will commence trading in the United States on the OTC Pink Market under the ticker symbol "CLABF".

The common shares of the Company are eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company.

Upon commencement of trading, investors in the United States can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com. The Company's listing on the OTC Pink Market provides transparent trading for U.S. investors, strengthens the Company's U.S. shareholder base, and increases the liquidity of the Company's common shares.

The Company's common shares will continue to trade on the Canadian Securities Exchange under the symbol "COOL", and on the Frankfurt Exchange under "LD62, WKN: A2P8K3".

"We are very excited to be trading on the OTC Pink Market. This milestone opens Core One Labs to a broader market and larger investor base, while also providing current and prospective shareholders greater accessibility and liquidity in the trading of the Company's common shares. Additionally this US listing, in general, will provide greater exposure for the Company in the rapidly growing emerging psychedelics as alternative medicine space." stated Joel Shacker CEO of the Company.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the "technology") which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.